Zacks.com users have recently been watching Altria (MO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
I maintain a 'hold' rating for Altria Group due to its declining market share and the ongoing reduction in smoking rates. Despite attractive valuation and growth in segments like NJOY and on!, overall market share and cigarette volume continue to decline. Revenue growth is driven by higher pricing, but this isn't enough to offset the weaknesses in the company's core markets.
3 Reasons to Buy Altria Stock Like There's No Tomorrow
The recent surge across the markets, led by sectors like tech, energy, financials, and industrials, demonstrates that volatility surrounding election results can often drive attention away from more conservative, income-focused investments.
Philip Morris, Altria and British American Tobacco are included in this Analyst Blog.
During Q3 earnings, Altria showed strong price appreciation thanks to continued growth in NJOY and on!. Smokeable products continued to see lower volumes due to consumers becoming more health conscious, which will continue to be a risk for the company going forward. Altria was able to offset this with accelerated buybacks, significantly higher than the previous year's quarter.
Altria's stock is up by more than 30% over the past year, with a recent, and sizable, post-earnings jump. Is it worth this price?
The Fed cut short-term rates again — making decent yields even more attractive. But there are some dividend gems to be found in the S&P 500.
It's time to reassess the stock after Altria's surge this year.
The company was the subject of a bullish research update on the back of a convincing quarterly earnings beat.
Zacks.com users have recently been watching Altria (MO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
I see Altria benefiting from the shift to smoke-free products as the NJOY and on! brands gain volume while cigarette sales fall. NJOY's device shipments tripled in Q3 2024 with the FDA approving its menthol e-cigarettes, improving its market share to 6.2%. The proliferation of illicit e-vapor products and the ongoing patent fight with Juul pose significant risks to Altria's market share and growth.